Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
- 1Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 2Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Québec, Canada
- 3Medical Research Institute of New Zealand, Wellington, New Zealand
- Corresponding author: Dr Simon Couillard (s.couillard{at}usherbrooke.ca)
Abstract
The prototype ORACLE scale based on two simple measures of type 2 airway inflammation – blood eosinophils and FeNO – quantifies the excess risk conferred by raised biomarkers which is removed by type-2 anti-inflammatory treatment in trial populations.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Simon Couillard received a non-restricted research grant from Sanofi-Genzyme for investigator-initiated type 2 innovation research and received speaker honoraria from GlaxoSmithKline, Sanofi-Regeneron and AstraZeneca; outside the submitted work.
Conflict of interest: William Il Hoon Do is co-founder and sharehold of the Albus Health company; outside the submitted work.
Conflict of interest: Richard Beasley has received honoraria for presentations or consulting in Adboards from AstraZeneca, Asthma and Respiratory Foundation of New Zealand, Avillion, Cipla and Theravance; and research grants from AstraZeneca, CureKids (NZ), Genentech, and the Health Research Council of New Zealand.
Conflict of interest: Timothy S. C. Hinks has received grants from the Wellcome Trust, The Guardians of the Beit Fellowship, Pfizer Inc., Kymab Ltd, University of Oxford, Sensyne Health and Sanofi Genzyme; outside the submitted work. He has received personal fees from Astra Zeneca, personal fees from TEVA, personal fees from Omniprex and personal fees from Peer Voice outside the submitted work.
Conflict of interest: Ian D. Pavord In the last 5 years, IP has received speaker's honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine AB, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini, and GSK, and payments for organising educational events from AstraZeneca, GSK, Sanofi/Regeneron, and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi, and Knopp, and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, AstraZeneca, Teva, and Chiesi. He has received grants from Chiesi and Sanofi Genzyme. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer, and Insmed. In 2014-2015 he was an expert witness for a patent dispute involving AstraZeneca and Teva.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received September 30, 2021.
- Accepted December 17, 2021.
- Copyright ©The authors 2022
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org